Primus In News
Tarnished by cough syrup deaths, India’s pharma industry tries to look beyond the stupor
21-07-2023
Nilaya Varma, Co-Founder and CEO of Primus Partners shares his views on the impact of the COVID-19 pandemic and the Russia-Ukraine war on vaccine exports from India, especially to African and Commonwealth of Independent States (CIS) countries. In addition, he stresses that the increasing cost of raw materials and the withdrawal of GST exemption has exacerbated challenges for Indian pharma companies. Read Now!
Explore Related Insights
- Shipping costs, delivery time to rise amid Red Sea crisis
- Primus Partners Survey Reveals Optimistic Outlook for Viksit Bharat: Indians Express Confidence and 33 Experts Chart the Roadmap for Amrit Kaal
- Digital Data Protection: Vague and Unclear
- Want to fly high in the drone industry? Check out these in-demand roles and skills